Research Article
Polymorphisms of the DNA Methyltransferase 1 Gene Predict Survival of Gastric Cancer Patients Receiving Tumorectomy
Table 3
Associations between the SNPs and overall survival of gastric cancer patients.
| | Genotypes | Overall patients | Mean OS | HR (95% CI) | | Adjusted HR (95% CI) | Adjusted | | (%) | Deaths |
| | rs10420321 | | | | | | | | | AA | 130 (33.6) | 62 | 50.0 | 1.00 | | 1.00 | | | AG | 189 (48.8) | 85 | 53.6 | 0.90 (0.65–1.24) | 0.510 | 0.91 (0.65–1.26) | 0.553 | | GG | 68 (17.6) | 32 | 52.1 | 0.97 (0.63–1.49) | 0.890 | 0.98 (0.64–1.50) | 0.917 | | Dominant | | | | | | | | | AA | 130 (33.6) | 62 | 50.0 | 1.00 | | 1.00 | | | AG/GG | 257 (66.4) | 117 | 53.3 | 0.90 (0.67–1.24) | 0.490 | 0.92 (0.68–1.26) | 0.618 | | Recessive | | | | | | | | | AA/AG | 319 (82.4) | 147 | 52.4 | 1.00 | | 1.00 | | | GG | 68 (17.6) | 32 | 52.1 | 1.04 (0.71–1.52) | 0.730 | 1.04 (0.70–1.52) | 0.857 | | rs16999593 | | | | | | | | | TT | 268 (63.5) | 127 | 51.3 | 1.00 | | 1.00 | | | TC | 135 (32.0) | 63 | 52.3 | 0.98 (0.72–1.32) | 0.891 | 0.99 (0.73–1.34) | 0.986 | | CC | 19 (4.5) | 7 | 50.5 | 0.80 (0.37–1.70) | 0.555 | 0.80 (0.37–1.72) | 0.802 | | Dominant | | | | | | | | | TT | 268 (63.5) | 127 | 51.3 | 1.00 | | 1.00 | | | TC/CC | 154 (36.5) | 70 | 52.9 | 0.96 (0.72–1.28) | 0.767 | 0.96 (0.72–1.29) | 0.801 | | Recessive | | | | | | | | | TT/TC | 403 (95.5) | 190 | 51.8 | 1.00 | | 1.00 | | | CC | 19 (4.5) | 7 | 50.5 | 0.80 (0.38–1.70) | 0.471 | 0.81 (0.38–1.72) | 0.576 | | rs2228612 | | | | | | | | | TT | 137 (32.4) | 65 | 50.1 | 1.00 | | 1.00 | | | TC | 197 (46.7) | 90 | 52.9 | 0.92 (0.67–1.27) | 0.629 | 0.92 (0.67–1.27) | 0.614 | | CC | 88 (20.9) | 42 | 51.3 | 1.00 (0.68–1.47) | 1.000 | 1.03 (0.70–1.53) | 0.864 | | Dominant | | | | | | | | | TT | 137 (32.4) | 65 | 50.1 | 1.00 | | 1.00 | | | TC/CC | 285 (67.6) | 132 | 52.5 | 0.95 (0.70–1.27) | 0.720 | 0.96 (0.71–1.29) | 0.760 | | Recessive | | | | | | | | | TT/TC | 334 (79.1) | 155 | 52.0 | 1.00 | | 1.00 | | | CC | 88 (20.9) | 42 | 51.3 | 1.05 (0.75–1.47) | 0.790 | 1.09 (0.77–1.53) | 0.638 | | rs2228611 | | | | | | | | | GG | 221 (52.6) | 117 | 47.8 | 1.00 | | 1.00 | | | GA | 169 (40.3) | 66 | 57.5 | 0.66 (0.48–0.89) | 0.006 | 0.65 (0.48–0.88) | 0.006 | | AA | 30 (7.1) | 13 | 45.9 | 0.81 (0.46–1.44) | 0.469 | 0.80 (0.45–1.42) | 0.444 | | Dominant | | | | | | | | | GG | 221 (52.6) | 117 | 47.8 | 1.00 | | 1.00 | | | GA/AA | 199 (47.4) | 79 | 56.7 | 0.68 (0.51–0.90) | 0.007 | 0.67 (0.51–0.90) | 0.007 | | Recessive | | | | | | | | | GG/GA | 390 (92.9) | 183 | 52.1 | 1.00 | | 1.00 | | | AA | 30 (7.1) | 13 | 45.9 | 0.96 (0.55–1.69) | 0.894 | 0.95 (0.54–1.68) | 0.860 | | rs2288349 | | | | | | | | | GG | 237 (56.6) | 102 | 54.7 | 1.00 | | 1.00 | | | GA | 151 (36.0) | 77 | 47.4 | 1.27 (0.95–1.71) | 0.1105 | 1.26 (0.94–1.70) | 0.128 | | AA | 31 (7.4) | 17 | 46.0 | 1.39 (0.84–2.33) | 0.204 | 1.37 (0.82–2.30) | 0.228 | | Dominant | | | | | | | | | GG | 237 (56.6) | 102 | 54.7 | 1.00 | | 1.00 | | | GA/AA | 182 (43.4) | 94 | 47.7 | 1.29 (0.98–1.71) | 0.072 | 1.28 (0.97–1.70) | 0.086 | | Recessive | | | | | | | | | GG/GA | 388 (92.6) | 179 | 52.4 | 1.00 | | 1.00 | | | AA | 31 (7.4) | 17 | 46.0 | 1.27 (0.77–2.08) | 0.353 | 1.25 (0.76–2.06) | 0.376 |
|
|
OS: overall survival; HR: hazard ratio; CI: confidence interval.
Adjusted for age, sex, TNM stage, and postoperational chemotherapy.
|
